Vedere Bio II, Inc.® is a company developing next generation ocular gene therapies designed for vision restoration and preservation for patients with vision loss due to photoreceptor death.
Location: United States, Massachusetts, Cambridge
Employees: 11-50
Total raised: $77M
Founded date: 2020
Investors 4
| Date | Name | Website |
| - | Mission Bi... | missionbio... |
| - | Octagon Ca... | octagoninv... |
| - | Atlas Vent... | atlasventu... |
| - | Retinal De... | retinaldeg... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 18.05.2021 | Series A | $77M | - |
Mentions in press and media 4
| Date | Title | Description |
| 01.08.2023 | Startups shutting down in 2023: Tech startups that closed up shops in Q2 as venture market cools | It is undeniable that 2023 has been a challenging year for tech startups across the globe. The initial optimism that started at the beginning of this year quickly gave way to a daunting combination of banking defaults and Federal Reserve in... |
| 22.06.2021 | Vedere Bio II Announces Appointment of Gabor Veres, Ph.D., as Chief Scientific Officer | |
| 18.05.2021 | Vedere Bio II Launches with $77 Million Series A Financing to Develop Next Generation Ocular Gene Therapies | |
| 18.05.2021 | Vedere Bio II Secures $77M Series A Funding | CAMBRIDGE, MA, Vedere Bio II today announced the completion of its $77 million Series A financing. >> Click here for more funding data on Vedere Bio II >> To export Vedere Bio II funding data to PDF and Excel, click here ... |